ID   CSKP_HUMAN              Reviewed;         926 AA.
AC   O14936; A6NES1; B7ZKY0; O43215; Q17RI4; Q59HA0; Q5VT16; Q5VT17; Q5VT18;
AC   Q5VT19; Q66T42; Q9BYH6; Q9NYB2; Q9NYB3;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   17-APR-2007, sequence version 3.
DT   12-OCT-2022, entry version 233.
DE   RecName: Full=Peripheral plasma membrane protein CASK {ECO:0000305};
DE            Short=hCASK;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:18423203};
DE   AltName: Full=Calcium/calmodulin-dependent serine protein kinase;
DE   AltName: Full=Protein lin-2 homolog;
GN   Name=CASK {ECO:0000312|HGNC:HGNC:1497}; Synonyms=LIN2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND INTERACTION WITH SDC2 AND
RP   EPB41.
RC   TISSUE=Brain, Liver, and Lung;
RX   PubMed=9660868; DOI=10.1083/jcb.142.1.129;
RA   Cohen A.R., Woods D.F., Marfatia S.M., Walther Z., Chishti A.H.,
RA   Anderson J.M.;
RT   "Human CASK/LIN-2 binds syndecan-2 and protein 4.1 and localizes to the
RT   basolateral membrane of epithelial cells.";
RL   J. Cell Biol. 142:129-138(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Zha D., Hu G.;
RT   "The human homolog of the rat CASK, Drosophila Camguk and C.elegans Lin-2
RT   genes.";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Kidney;
RA   Ding L., Saijo K., Kawai K., Akaza H., Ugai H., Yokoyama K.K., Ohno T.;
RT   "Putative alternative splicing form of human CASK mRNA (partial codes).";
RL   Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Colon carcinoma;
RA   Yan Y., Merlin D.;
RT   "Caco2-BBE calcium/calmodulin-dependent serine protein kinase.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 5-926 (ISOFORM 2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 173-926 (ISOFORM 1), NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 27-926 (ISOFORM 3), AND TISSUE SPECIFICITY.
RC   TISSUE=Fetus;
RX   PubMed=11003712; DOI=10.1007/s003350010170;
RA   Stevenson D., Laverty H.G., Wenwieser S., Douglas M., Wilson J.B.;
RT   "Mapping and expression analysis of the human CASK gene.";
RL   Mamm. Genome 11:934-937(2000).
RN   [9]
RP   INTERACTION WITH KIRREL3.
RX   PubMed=19012874; DOI=10.1016/j.ajhg.2008.10.020;
RA   Bhalla K., Luo Y., Buchan T., Beachem M.A., Guzauskas G.F., Ladd S.,
RA   Bratcher S.J., Schroer R.J., Balsamo J., DuPont B.R., Lilien J.,
RA   Srivastava A.K.;
RT   "Alterations in CDH15 and KIRREL3 in patients with mild to severe
RT   intellectual disability.";
RL   Am. J. Hum. Genet. 83:703-713(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-51, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-313, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-571 (ISOFORM 3), PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-577 (ISOFORM 4), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT
RP   SER-192 (ISOFORM 5), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 489-572.
RX   PubMed=9546224; DOI=10.1038/nsb0498-317;
RA   Daniels D.L., Cohen A.R., Anderson J.M., Bruenger A.T.;
RT   "Crystal structure of the hCASK PDZ domain reveals the structural basis of
RT   class II PDZ domain target recognition.";
RL   Nat. Struct. Biol. 5:317-325(1998).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1-337 IN COMPLEX WITH AMP,
RP   CATALYTIC ACTIVITY, COFACTOR, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, PHOSPHORYLATION OF NRXN1, AND PHOSPHORYLATION AT SER-151 AND
RP   SER-155.
RX   PubMed=18423203; DOI=10.1016/j.cell.2008.02.036;
RA   Mukherjee K., Sharma M., Urlaub H., Bourenkov G.P., Jahn R., Suedhof T.C.,
RA   Wahl M.C.;
RT   "CASK functions as a Mg2+-independent neurexin kinase.";
RL   Cell 133:328-339(2008).
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-96.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [15]
RP   INVOLVEMENT IN MICPCH SYNDROME.
RX   PubMed=19165920; DOI=10.1038/ng.194;
RA   Najm J., Horn D., Wimplinger I., Golden J.A., Chizhikov V.V., Sudi J.,
RA   Christian S.L., Ullmann R., Kuechler A., Haas C.A., Flubacher A.,
RA   Charnas L.R., Uyanik G., Frank U., Klopocki E., Dobyns W.B., Kutsche K.;
RT   "Mutations of CASK cause an X-linked brain malformation phenotype with
RT   microcephaly and hypoplasia of the brainstem and cerebellum.";
RL   Nat. Genet. 40:1065-1067(2008).
RN   [16]
RP   ERRATUM OF PUBMED:19165920.
RA   Najm J., Horn D., Wimplinger I., Golden J.A., Chizhikov V.V., Sudi J.,
RA   Christian S.L., Ullmann R., Kuechler A., Haas C.A., Flubacher A.,
RA   Charnas L.R., Uyanik G., Frank U., Klopocki E., Dobyns W.B., Kutsche K.;
RL   Nat. Genet. 40:1384-1384(2008).
RN   [17]
RP   VARIANT FGS4 LEU-28, AND CHARACTERIZATION OF VARIANT FGS4 LEU-28.
RX   PubMed=19200522; DOI=10.1016/j.ajhg.2008.12.018;
RA   Piluso G., D'Amico F., Saccone V., Bismuto E., Rotundo I.L.,
RA   Di Domenico M., Aurino S., Schwartz C.E., Neri G., Nigro V.;
RT   "A missense mutation in CASK causes FG syndrome in an Italian family.";
RL   Am. J. Hum. Genet. 84:162-177(2009).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] MICPCH HIS-268; SER-396 AND GLY-710.
RX   PubMed=19377476; DOI=10.1038/ng.367;
RA   Tarpey P.S., Smith R., Pleasance E., Whibley A., Edkins S., Hardy C.,
RA   O'Meara S., Latimer C., Dicks E., Menzies A., Stephens P., Blow M.,
RA   Greenman C., Xue Y., Tyler-Smith C., Thompson D., Gray K., Andrews J.,
RA   Barthorpe S., Buck G., Cole J., Dunmore R., Jones D., Maddison M.,
RA   Mironenko T., Turner R., Turrell K., Varian J., West S., Widaa S., Wray P.,
RA   Teague J., Butler A., Jenkinson A., Jia M., Richardson D., Shepherd R.,
RA   Wooster R., Tejada M.I., Martinez F., Carvill G., Goliath R.,
RA   de Brouwer A.P., van Bokhoven H., Van Esch H., Chelly J., Raynaud M.,
RA   Ropers H.H., Abidi F.E., Srivastava A.K., Cox J., Luo Y., Mallya U.,
RA   Moon J., Parnau J., Mohammed S., Tolmie J.L., Shoubridge C., Corbett M.,
RA   Gardner A., Haan E., Rujirabanjerd S., Shaw M., Vandeleur L., Fullston T.,
RA   Easton D.F., Boyle J., Partington M., Hackett A., Field M., Skinner C.,
RA   Stevenson R.E., Bobrow M., Turner G., Schwartz C.E., Gecz J., Raymond F.L.,
RA   Futreal P.A., Stratton M.R.;
RT   "A systematic, large-scale resequencing screen of X-chromosome coding exons
RT   in mental retardation.";
RL   Nat. Genet. 41:535-543(2009).
RN   [19]
RP   VARIANT 19-GLY--TYR-926 DEL.
RX   PubMed=23662938; DOI=10.1111/epi.12203;
RA   Kodera H., Kato M., Nord A.S., Walsh T., Lee M., Yamanaka G., Tohyama J.,
RA   Nakamura K., Nakagawa E., Ikeda T., Ben-Zeev B., Lev D., Lerman-Sagie T.,
RA   Straussberg R., Tanabe S., Ueda K., Amamoto M., Ohta S., Nonoda Y.,
RA   Nishiyama K., Tsurusaki Y., Nakashima M., Miyake N., Hayasaka K.,
RA   King M.C., Matsumoto N., Saitsu H.;
RT   "Targeted capture and sequencing for detection of mutations causing early
RT   onset epileptic encephalopathy.";
RL   Epilepsia 54:1262-1269(2013).
CC   -!- FUNCTION: Multidomain scaffolding Mg(2+)-independent protein kinase
CC       that catalyzes the phosphotransfer from ATP to proteins such as NRXN1,
CC       and plays a role in synaptic transmembrane protein anchoring and ion
CC       channel trafficking (PubMed:18423203). Contributes to neural
CC       development and regulation of gene expression via interaction with the
CC       transcription factor TBR1. Binds to cell-surface proteins, including
CC       amyloid precursor protein, neurexins and syndecans. May mediate a link
CC       between the extracellular matrix and the actin cytoskeleton via its
CC       interaction with syndecan and with the actin/spectrin-binding protein
CC       4.1. Component of the LIN-10-LIN-2-LIN-7 complex, which associates with
CC       the motor protein KIF17 to transport vesicles containing N-methyl-D-
CC       aspartate (NMDA) receptor subunit NR2B along microtubules (By
CC       similarity). {ECO:0000250|UniProtKB:O70589,
CC       ECO:0000269|PubMed:18423203}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:18423203};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:18423203};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Note=Unlike other protein kinases, does not require a divalent cation
CC       such as magnesium for catalytic activity.
CC       {ECO:0000269|PubMed:18423203};
CC   -!- ACTIVITY REGULATION: Differs from archetypal CaMK members in that the
CC       kinase domain exhibits a constitutively active conformation and the
CC       autoinhibitory region does not engage in direct contact with the ATP-
CC       binding cleft, although it still binds Ca(2+)/CAM.
CC       {ECO:0000269|PubMed:18423203}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=563 uM for ATP {ECO:0000269|PubMed:18423203};
CC         KM=748.7 uM for ATP (when NRXN1 is phosphorylated)
CC         {ECO:0000269|PubMed:18423203};
CC         Vmax=4.9 nmol/min/mmol enzyme {ECO:0000269|PubMed:18423203};
CC         Note=Kinetics of autophosphorylation assay were measured, rather than
CC         phosphorylation of an exogenous substrate.;
CC   -!- SUBUNIT: CASK and LIN7 form two mutually exclusive tripartite complexes
CC       with APBA1 or CASKIN1 (By similarity). Component of the brain-specific
CC       heterotrimeric complex (LIN-10-LIN-2-LIN-7 complex) composed of at
CC       least APBA1, CASK, and LIN7, which associates with the motor protein
CC       KIF17 to transport vesicles along microtubules (By similarity). Forms a
CC       heterotrimeric complex with DLG1 and LIN7B via their L27 domains (By
CC       similarity). Identified in a complex with ACTN4, IQGAP1, MAGI2, NPHS1,
CC       SPTAN1 and SPTBN1 (By similarity). Part of a complex containing CASK,
CC       TBR1 and TSPYL2 (By similarity). Interacts with WHRN (By similarity).
CC       Interacts (via the PDZ, SH3 and guanylate kinase-like domains) with
CC       NRXN1 (via C-terminus) (By similarity). Interacts with CASKIN1, APBA1,
CC       LIN7(A/B/C) and L27 domain of DLG1 and isoform 2 of DLG4 (By
CC       similarity). Interacts with FCHSD2 (By similarity). Interacts with
CC       KIRREL3 (PubMed:19012874). Interacts with TBR1 (By similarity).
CC       Interacts with TSPYL2 (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:O70589, ECO:0000250|UniProtKB:Q62915,
CC       ECO:0000269|PubMed:18423203, ECO:0000269|PubMed:19012874,
CC       ECO:0000269|PubMed:9660868}.
CC   -!- INTERACTION:
CC       O14936; Q8WXD9: CASKIN1; NbExp=4; IntAct=EBI-1215506, EBI-970261;
CC       O14936; Q12929: EPS8; NbExp=3; IntAct=EBI-1215506, EBI-375576;
CC       O14936; P41134: ID1; NbExp=3; IntAct=EBI-1215506, EBI-1215527;
CC       O14936; O14910: LIN7A; NbExp=7; IntAct=EBI-1215506, EBI-2513988;
CC       O14936; Q9Y2J0: RPH3A; NbExp=3; IntAct=EBI-1215506, EBI-1216802;
CC       O14936; P34741: SDC2; NbExp=2; IntAct=EBI-1215506, EBI-1172957;
CC       O14936; Q9H788: SH2D4A; NbExp=4; IntAct=EBI-1215506, EBI-747035;
CC       O14936; Q13425: SNTB2; NbExp=3; IntAct=EBI-1215506, EBI-80411;
CC       O14936; Q13009: TIAM1; NbExp=2; IntAct=EBI-1215506, EBI-1050007;
CC       O14936; Q63373: Nrxn1; Xeno; NbExp=3; IntAct=EBI-1215506, EBI-1780696;
CC       O14936-2; Q8WXD9: CASKIN1; NbExp=2; IntAct=EBI-15957318, EBI-970261;
CC       O14936-4; Q9H1P6: C20orf85; NbExp=3; IntAct=EBI-12007726, EBI-12155483;
CC       O14936-4; O14910: LIN7A; NbExp=3; IntAct=EBI-12007726, EBI-2513988;
CC       O14936-4; Q9HAP6: LIN7B; NbExp=3; IntAct=EBI-12007726, EBI-821335;
CC       O14936-4; Q9UH92-3: MLX; NbExp=3; IntAct=EBI-12007726, EBI-8852072;
CC       O14936-4; Q9HB63: NTN4; NbExp=3; IntAct=EBI-12007726, EBI-743459;
CC       O14936-4; Q9H788: SH2D4A; NbExp=3; IntAct=EBI-12007726, EBI-747035;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q62915}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q62915}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q62915}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q62915}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=O14936-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14936-2; Sequence=VSP_024426;
CC       Name=3;
CC         IsoId=O14936-3; Sequence=VSP_024422, VSP_024424;
CC       Name=4;
CC         IsoId=O14936-4; Sequence=VSP_024424, VSP_024426;
CC       Name=5;
CC         IsoId=O14936-5; Sequence=VSP_024421, VSP_024423, VSP_024424;
CC       Name=6;
CC         IsoId=O14936-6; Sequence=VSP_024425, VSP_024426;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Expression is significantly greater in
CC       brain relative to kidney, lung, and liver and in fetal brain and kidney
CC       relative to lung and liver. {ECO:0000269|PubMed:11003712}.
CC   -!- DOMAIN: The first L27 domain binds DLG1 and the second L27 domain
CC       probably binds LIN7. {ECO:0000250}.
CC   -!- DOMAIN: The protein kinase domain mediates the interaction with FCHSD2.
CC   -!- DISEASE: Intellectual developmental disorder with microcephaly and
CC       pontine and cerebellar hypoplasia (MICPCH) [MIM:300749]: A disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period. Affected individuals can
CC       manifest a severe phenotype consisting of severe intellectual deficit,
CC       congenital or postnatal microcephaly, disproportionate brainstem and
CC       cerebellar hypoplasia. A milder phenotype consists of intellectual
CC       disability alone or associated with nystagmus.
CC       {ECO:0000269|PubMed:19165920, ECO:0000269|PubMed:19377476}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: FG syndrome 4 (FGS4) [MIM:300422]: FG syndrome (FGS) is an X-
CC       linked disorder characterized by intellectual disability, relative
CC       macrocephaly, hypotonia and constipation.
CC       {ECO:0000269|PubMed:19200522}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the protein kinase
CC       superfamily. CAMK Ser/Thr protein kinase family. CaMK subfamily.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the MAGUK family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF032119; AAB88125.1; -; mRNA.
DR   EMBL; AF035582; AAB88198.1; -; mRNA.
DR   EMBL; AB039327; BAB12252.2; -; mRNA.
DR   EMBL; AY705392; AAU10527.1; -; mRNA.
DR   EMBL; AL158144; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353691; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445239; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL603754; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL627402; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117311; AAI17312.1; -; mRNA.
DR   EMBL; BC143454; AAI43455.1; -; mRNA.
DR   EMBL; AB208859; BAD92096.1; -; mRNA.
DR   EMBL; AF262404; AAF72666.1; -; mRNA.
DR   EMBL; AF262405; AAF72667.1; -; mRNA.
DR   CCDS; CCDS14257.1; -. [O14936-2]
DR   CCDS; CCDS48094.1; -. [O14936-3]
DR   CCDS; CCDS48095.1; -. [O14936-4]
DR   RefSeq; NP_001119526.1; NM_001126054.2. [O14936-4]
DR   RefSeq; NP_001119527.1; NM_001126055.2. [O14936-3]
DR   RefSeq; NP_003679.2; NM_003688.3. [O14936-2]
DR   PDB; 1KGD; X-ray; 1.31 A; A=739-914.
DR   PDB; 1KWA; X-ray; 1.93 A; A/B=487-572.
DR   PDB; 1ZL8; NMR; -; B=403-456.
DR   PDB; 3C0G; X-ray; 2.19 A; A/B=1-337.
DR   PDB; 3C0H; X-ray; 2.30 A; A/B=1-337.
DR   PDB; 3C0I; X-ray; 1.85 A; A=1-337.
DR   PDB; 3MFR; X-ray; 2.00 A; A=1-337.
DR   PDB; 3MFS; X-ray; 2.10 A; A=1-337.
DR   PDB; 3MFT; X-ray; 2.20 A; A=1-337.
DR   PDB; 3MFU; X-ray; 2.30 A; A=1-337.
DR   PDB; 3TAC; X-ray; 2.20 A; A=1-345.
DR   PDB; 6KMH; X-ray; 2.40 A; A/B=1-319.
DR   PDB; 7OAI; X-ray; 2.30 A; A/B/C/D=1-337.
DR   PDB; 7OAJ; X-ray; 1.93 A; A/B/C/D=1-337.
DR   PDB; 7OAK; X-ray; 2.23 A; A/B/C/D=1-337.
DR   PDB; 7OAL; X-ray; 2.17 A; A/B/C/D=1-337.
DR   PDBsum; 1KGD; -.
DR   PDBsum; 1KWA; -.
DR   PDBsum; 1ZL8; -.
DR   PDBsum; 3C0G; -.
DR   PDBsum; 3C0H; -.
DR   PDBsum; 3C0I; -.
DR   PDBsum; 3MFR; -.
DR   PDBsum; 3MFS; -.
DR   PDBsum; 3MFT; -.
DR   PDBsum; 3MFU; -.
DR   PDBsum; 3TAC; -.
DR   PDBsum; 6KMH; -.
DR   PDBsum; 7OAI; -.
DR   PDBsum; 7OAJ; -.
DR   PDBsum; 7OAK; -.
DR   PDBsum; 7OAL; -.
DR   AlphaFoldDB; O14936; -.
DR   SMR; O14936; -.
DR   BioGRID; 114141; 171.
DR   CORUM; O14936; -.
DR   DIP; DIP-38727N; -.
DR   ELM; O14936; -.
DR   IntAct; O14936; 93.
DR   MINT; O14936; -.
DR   STRING; 9606.ENSP00000367408; -.
DR   BindingDB; O14936; -.
DR   ChEMBL; CHEMBL1908381; -.
DR   DrugBank; DB01942; Formic acid.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O14936; -.
DR   GlyGen; O14936; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O14936; -.
DR   PhosphoSitePlus; O14936; -.
DR   SwissPalm; O14936; -.
DR   BioMuta; CASK; -.
DR   EPD; O14936; -.
DR   jPOST; O14936; -.
DR   MassIVE; O14936; -.
DR   MaxQB; O14936; -.
DR   PaxDb; O14936; -.
DR   PeptideAtlas; O14936; -.
DR   PRIDE; O14936; -.
DR   ProteomicsDB; 48318; -. [O14936-1]
DR   ProteomicsDB; 48319; -. [O14936-2]
DR   ProteomicsDB; 48320; -. [O14936-3]
DR   ProteomicsDB; 48321; -. [O14936-4]
DR   ProteomicsDB; 48322; -. [O14936-5]
DR   ProteomicsDB; 48323; -. [O14936-6]
DR   TopDownProteomics; O14936-5; -. [O14936-5]
DR   ABCD; O14936; 1 sequenced antibody.
DR   Antibodypedia; 4529; 310 antibodies from 38 providers.
DR   DNASU; 8573; -.
DR   Ensembl; ENST00000378154.3; ENSP00000367396.2; ENSG00000147044.23. [O14936-6]
DR   Ensembl; ENST00000378163.7; ENSP00000367405.1; ENSG00000147044.23. [O14936-1]
DR   Ensembl; ENST00000644347.1; ENSP00000494183.1; ENSG00000147044.23. [O14936-3]
DR   Ensembl; ENST00000645566.1; ENSP00000494788.1; ENSG00000147044.23. [O14936-2]
DR   Ensembl; ENST00000646120.2; ENSP00000495291.2; ENSG00000147044.23. [O14936-4]
DR   GeneID; 8573; -.
DR   KEGG; hsa:8573; -.
DR   MANE-Select; ENST00000378163.7; ENSP00000367405.1; NM_001367721.1; NP_001354650.1.
DR   UCSC; uc004dfl.5; human. [O14936-1]
DR   CTD; 8573; -.
DR   DisGeNET; 8573; -.
DR   GeneCards; CASK; -.
DR   GeneReviews; CASK; -.
DR   HGNC; HGNC:1497; CASK.
DR   HPA; ENSG00000147044; Low tissue specificity.
DR   MalaCards; CASK; -.
DR   MIM; 300172; gene.
DR   MIM; 300422; phenotype.
DR   MIM; 300749; phenotype.
DR   neXtProt; NX_O14936; -.
DR   OpenTargets; ENSG00000147044; -.
DR   Orphanet; 1934; Early infantile epileptic encephalopathy.
DR   Orphanet; 323; NON RARE IN EUROPE: FG syndrome phenotypic spectrum.
DR   Orphanet; 163937; X-linked intellectual disability, Najm type.
DR   PharmGKB; PA26081; -.
DR   VEuPathDB; HostDB:ENSG00000147044; -.
DR   eggNOG; KOG0033; Eukaryota.
DR   eggNOG; KOG0609; Eukaryota.
DR   GeneTree; ENSGT00940000155600; -.
DR   HOGENOM; CLU_001715_5_3_1; -.
DR   InParanoid; O14936; -.
DR   OrthoDB; 95102at2759; -.
DR   PhylomeDB; O14936; -.
DR   TreeFam; TF314263; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   BRENDA; 2.7.4.8; 2681.
DR   PathwayCommons; O14936; -.
DR   Reactome; R-HSA-212676; Dopamine Neurotransmitter Release Cycle.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-373753; Nephrin family interactions.
DR   Reactome; R-HSA-6794361; Neurexins and neuroligins.
DR   Reactome; R-HSA-9609736; Assembly and cell surface presentation of NMDA receptors.
DR   Reactome; R-HSA-9662360; Sensory processing of sound by inner hair cells of the cochlea.
DR   Reactome; R-HSA-9662361; Sensory processing of sound by outer hair cells of the cochlea.
DR   SABIO-RK; O14936; -.
DR   SignaLink; O14936; -.
DR   SIGNOR; O14936; -.
DR   BioGRID-ORCS; 8573; 13 hits in 730 CRISPR screens.
DR   ChiTaRS; CASK; human.
DR   EvolutionaryTrace; O14936; -.
DR   GeneWiki; CASK; -.
DR   GenomeRNAi; 8573; -.
DR   Pharos; O14936; Tchem.
DR   PRO; PR:O14936; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O14936; protein.
DR   Bgee; ENSG00000147044; Expressed in buccal mucosa cell and 209 other tissues.
DR   ExpressionAtlas; O14936; baseline and differential.
DR   Genevisible; O14936; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005604; C:basement membrane; IDA:CACAO.
DR   GO; GO:0016323; C:basolateral plasma membrane; IBA:GO_Central.
DR   GO; GO:0005911; C:cell-cell junction; IDA:BHF-UCL.
DR   GO; GO:0060170; C:ciliary membrane; ISS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005652; C:nuclear lamina; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:BHF-UCL.
DR   GO; GO:0005730; C:nucleolus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0042734; C:presynaptic membrane; ISS:BHF-UCL.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0031982; C:vesicle; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0004385; F:guanylate kinase activity; TAS:ProtInc.
DR   GO; GO:0042043; F:neurexin family protein binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:FlyBase.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0070509; P:calcium ion import; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IMP:BHF-UCL.
DR   GO; GO:0090288; P:negative regulation of cellular response to growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IDA:CACAO.
DR   GO; GO:0061045; P:negative regulation of wound healing; IMP:BHF-UCL.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0008104; P:protein localization; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0046928; P:regulation of neurotransmitter secretion; IBA:GO_Central.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl.
DR   CDD; cd12081; SH3_CASK; 1.
DR   DisProt; DP01438; -.
DR   Gene3D; 2.30.42.10; -; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR035473; CASK_SH3.
DR   InterPro; IPR008145; GK/Ca_channel_bsu.
DR   InterPro; IPR008144; Guanylate_kin-like_dom.
DR   InterPro; IPR020590; Guanylate_kinase_CS.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR014775; L27_C.
DR   InterPro; IPR004172; L27_dom.
DR   InterPro; IPR036892; L27_dom_sf.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR036034; PDZ_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   Pfam; PF00625; Guanylate_kin; 1.
DR   Pfam; PF02828; L27; 2.
DR   Pfam; PF00595; PDZ; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   SMART; SM00072; GuKc; 1.
DR   SMART; SM00569; L27; 2.
DR   SMART; SM00228; PDZ; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF101288; SSF101288; 2.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF50156; SSF50156; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00856; GUANYLATE_KINASE_1; 1.
DR   PROSITE; PS50052; GUANYLATE_KINASE_2; 1.
DR   PROSITE; PS51022; L27; 2.
DR   PROSITE; PS50106; PDZ; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calmodulin-binding;
KW   Cell membrane; Cytoplasm; Disease variant; Intellectual disability; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; Serine/threonine-protein kinase; SH3 domain; Transferase.
FT   CHAIN           1..926
FT                   /note="Peripheral plasma membrane protein CASK"
FT                   /id="PRO_0000094568"
FT   DOMAIN          12..276
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          343..398
FT                   /note="L27 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00365"
FT   DOMAIN          402..455
FT                   /note="L27 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00365"
FT   DOMAIN          489..564
FT                   /note="PDZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          612..682
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          739..911
FT                   /note="Guanylate kinase-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00100"
FT   REGION          305..315
FT                   /note="Calmodulin-binding"
FT   REGION          482..909
FT                   /note="Required for interaction with NRXN1 (via C-terminal
FT                   tail)"
FT                   /evidence="ECO:0000250|UniProtKB:Q62915"
FT   REGION          574..610
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        141
FT                   /evidence="ECO:0000250"
FT   BINDING         18..26
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00100,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         41
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         51
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         151
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18423203"
FT   MOD_RES         155
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18423203"
FT   MOD_RES         182
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O70589"
FT   MOD_RES         313
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         1..385
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_024421"
FT   VAR_SEQ         340..345
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11003712, ECO:0000303|Ref.2"
FT                   /id="VSP_024422"
FT   VAR_SEQ         386
FT                   /note="L -> M (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_024423"
FT   VAR_SEQ         580..602
FT                   /note="Missing (in isoform 3, isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11003712,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|Ref.2,
FT                   ECO:0000303|Ref.3"
FT                   /id="VSP_024424"
FT   VAR_SEQ         603..614
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_024425"
FT   VAR_SEQ         719..723
FT                   /note="Missing (in isoform 2, isoform 4 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9660868, ECO:0000303|Ref.4,
FT                   ECO:0000303|Ref.7"
FT                   /id="VSP_024426"
FT   VARIANT         19..926
FT                   /note="Missing (probable disease-associated variant found
FT                   in a patient with epilepsy and pontocerebellar hypoplasia)"
FT                   /evidence="ECO:0000269|PubMed:23662938"
FT                   /id="VAR_078710"
FT   VARIANT         28
FT                   /note="R -> L (in FGS4; does not reveal significant
FT                   alterations induced by the mutation substitution; causes a
FT                   partial skipping of exon 2 of the protein;
FT                   dbSNP:rs137852816)"
FT                   /evidence="ECO:0000269|PubMed:19200522"
FT                   /id="VAR_058719"
FT   VARIANT         96
FT                   /note="G -> V (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041956"
FT   VARIANT         268
FT                   /note="Y -> H (in MICPCH; dbSNP:rs137852817)"
FT                   /evidence="ECO:0000269|PubMed:19377476"
FT                   /id="VAR_062996"
FT   VARIANT         396
FT                   /note="P -> S (in MICPCH; dbSNP:rs137852820)"
FT                   /evidence="ECO:0000269|PubMed:19377476"
FT                   /id="VAR_062997"
FT   VARIANT         710
FT                   /note="D -> G (in MICPCH; dbSNP:rs137852818)"
FT                   /evidence="ECO:0000269|PubMed:19377476"
FT                   /id="VAR_062998"
FT   CONFLICT        401
FT                   /note="P -> L (in Ref. 2; AAB88198)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        479
FT                   /note="D -> G (in Ref. 1; AAB88125, 3; BAB12252, 4;
FT                   AAU10527 and 8; AAF72666/AAF72667)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        675
FT                   /note="P -> S (in Ref. 1; AAB88125 and 4; AAU10527)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        780
FT                   /note="K -> R (in Ref. 1; AAB88125 and 4; AAU10527)"
FT                   /evidence="ECO:0000305"
FT   HELIX           8..11
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          12..20
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          22..31
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   TURN            32..34
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          37..44
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           45..49
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          51..53
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           56..68
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          77..83
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          86..92
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           99..108
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           115..134
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           144..146
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          147..149
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          151..153
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   STRAND          158..160
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           163..165
FT                   /evidence="ECO:0007829|PDB:3TAC"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:3MFS"
FT   HELIX           183..185
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           188..191
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           199..214
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           223..232
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           239..242
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           247..256
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   TURN            261..263
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           267..271
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           274..277
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           279..282
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   HELIX           289..302
FT                   /evidence="ECO:0007829|PDB:3C0I"
FT   TURN            304..306
FT                   /evidence="ECO:0007829|PDB:3TAC"
FT   HELIX           309..312
FT                   /evidence="ECO:0007829|PDB:3C0G"
FT   STRAND          314..316
FT                   /evidence="ECO:0007829|PDB:3C0G"
FT   HELIX           404..416
FT                   /evidence="ECO:0007829|PDB:1ZL8"
FT   HELIX           423..431
FT                   /evidence="ECO:0007829|PDB:1ZL8"
FT   HELIX           437..450
FT                   /evidence="ECO:0007829|PDB:1ZL8"
FT   STRAND          489..495
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   STRAND          497..499
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   STRAND          503..506
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   HELIX           510..512
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   STRAND          513..518
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   HELIX           523..527
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   STRAND          535..539
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   HELIX           544..546
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   HELIX           549..558
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   STRAND          561..568
FT                   /evidence="ECO:0007829|PDB:1KWA"
FT   STRAND          741..745
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   HELIX           752..762
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   TURN            764..766
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   TURN            784..786
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   HELIX           793..801
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   STRAND          805..811
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   STRAND          814..819
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   HELIX           820..828
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   STRAND          832..836
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   HELIX           839..841
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   HELIX           842..845
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   TURN            848..850
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   STRAND          852..858
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   HELIX           870..886
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   HELIX           887..889
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   STRAND          891..895
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   HELIX           899..913
FT                   /evidence="ECO:0007829|PDB:1KGD"
FT   MOD_RES         O14936-3:571
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         O14936-4:577
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         O14936-5:192
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
SQ   SEQUENCE   926 AA;  105123 MW;  6C02008CE52728BA CRC64;
     MADDDVLFED VYELCEVIGK GPFSVVRRCI NRETGQQFAV KIVDVAKFTS SPGLSTEDLK
     REASICHMLK HPHIVELLET YSSDGMLYMV FEFMDGADLC FEIVKRADAG FVYSEAVASH
     YMRQILEALR YCHDNNIIHR DVKPHCVLLA SKENSAPVKL GGFGVAIQLG ESGLVAGGRV
     GTPHFMAPEV VKREPYGKPV DVWGCGVILF ILLSGCLPFY GTKERLFEGI IKGKYKMNPR
     QWSHISESAK DLVRRMLMLD PAERITVYEA LNHPWLKERD RYAYKIHLPE TVEQLRKFNA
     RRKLKGAVLA AVSSHKFNSF YGDPPEELPD FSEDPTSSGL LAAERAVSQV LDSLEEIHAL
     TDCSEKDLDF LHSVFQDQHL HTLLDLYDKI NTKSSPQIRN PPSDAVQRAK EVLEEISCYP
     ENNDAKELKR ILTQPHFMAL LQTHDVVAHE VYSDEALRVT PPPTSPYLNG DSPESANGDM
     DMENVTRVRL VQFQKNTDEP MGITLKMNEL NHCIVARIMH GGMIHRQGTL HVGDEIREIN
     GISVANQTVE QLQKMLREMR GSITFKIVPS YRTQSSSCER DSPSTSRQSP ANGHSSTNNS
     VSDLPSTTQP KGRQIYVRAQ FEYDPAKDDL IPCKEAGIRF RVGDIIQIIS KDDHNWWQGK
     LENSKNGTAG LIPSPELQEW RVACIAMEKT KQEQQASCTW FGKKKKQYKD KYLAKHNAVF
     DQLDLVTYEE VVKLPAFKRK TLVLLGAHGV GRRHIKNTLI TKHPDRFAYP IPHTTRPPKK
     DEENGKNYYF VSHDQMMQDI SNNEYLEYGS HEDAMYGTKL ETIRKIHEQG LIAILDVEPQ
     ALKVLRTAEF APFVVFIAAP TITPGLNEDE SLQRLQKESD ILQRTYAHYF DLTIINNEID
     ETIRHLEEAV ELVCTAPQWV PVSWVY
//
